Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multiferon is a multi-subtype, human leukocyte-derived interferon-alpha (IFN-α) preparation. It consists of a natural mixture of several interferon-alpha subtypes produced by human white blood cells (leukocytes) after induction with Sendai virus. Unlike recombinant interferons which consist of a single subtype, Multiferon's natural composition is intended to mimic the body's endogenous response. In the context of multiple sclerosis (MS), it has been investigated as a rescue or alternative therapy for patients who have developed neutralizing antibodies (NAbs) against interferon-beta (IFN-β). By binding to the Type I interferon receptor (IFNAR), Multiferon activates the JAK-STAT signaling pathway, leading to the transcription of interferon-stimulated genes that exert immunomodulatory, antiviral, and antiproliferative effects, potentially reducing the inflammatory activity associated with MS relapses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Multiferon.